EJPMR, 2026, 13(6), 432-439 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

ANTIMICROBIAL RESISTANCE AND ITS CONSEQUENCES FOR INFECTION CONTROL AND GLOBAL PUBLIC HEALTH

Patrick Chimuanya Etus[1], Micheal Abimbola Oladosu[2]*, Moses Adondua Abah[3], Okabeonye Sunday Agbo[4], Bukola Oluwaseyi Olufosoye[5], Comfort Oluwakemi Cambell[6]

[1]Department of Graduate Business Studies, Faculty of Business, Ohio Dominican University, Ohio, USA.
[2]Department of Chemical Sciences, Faculty of Science, Anchor University, Lagos, Nigeria.
[3]Department of Biochemistry, Faculty of Pure and Applied Sciences, Federal University of Wukari, Wukari, Taraba State, Nigeria
[4]Department of Applied Biology and Biotechnology, Enugu State University of Science and Technology, Agbani, Nigeria.
[5]Department of Medical Microbiology, Faculty of Medical Laboratory Sciences. Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[6]Department of Biological Sciences, Anchor University, Ayobo, Lagos State, Nigeria.

***Corresponding Author: Micheal Abimbola Oladosu**

Department of Chemical Sciences, Faculty of Science, Anchor University, Lagos, Nigeria.

DOI: https://doi.org/10.5281/zenodo.20470828

How to cite this Article: Patrick Chimuanya Etus[1], Micheal Abimbola Oladosu[2]*, Moses Adondua Abah[3], Okabeonye Sunday Agbo[4], Bukola Oluwaseyi Olufosoye[5], Comfort Oluwakemi Cambell[6]. (2026). Antimicrobial Resistance And Its Consequences For Infection Control and Global Public Health. European Journal of Pharmaceuticaland Medical Research, 13(6), 432–439.

Article Received on 25/05/2026 **Article Revised on 25/05/2026** **Article Published on 01/06/2026**

ABSTRACT

Antimicrobial resistance (AMR) represents one of the most formidable threats to global public health, rendering previously treatable infections increasingly difficult or impossible to manage. The global burden of AMR accounts for an estimated 1.27 million directly attributable deaths annually, with mortality projections reaching 10 million per year by 2050 if current trajectories are not reversed. This review synthesises evidence from pharmaceutical science, clinical microbiology, infectious disease epidemiology, and health systems research published between 2020 and 2025 to critically examine the biological mechanisms underpinning AMR, its epidemiological distribution, and the cascade of consequences for infection prevention and control (IPC) in healthcare settings. We analyse the role of antimicrobial stewardship programmes (ASPs), WHO priority pathogen frameworks, global surveillance systems including the Global Antimicrobial Resistance and Use Surveillance System (GLASS), and the intersection of the One Health approach in combating AMR across human, animal, and environmental reservoirs. Emerging therapeutic innovations, including bacteriophage therapy, CRISPR-based antimicrobials, and novel beta-lactam/beta-lactamase inhibitor combinations, are critically appraised. The review concludes with policy recommendations for strengthening national action plans, reinforcing pharmaceutical pipelines, and achieving equitable AMR governance across low- and middle-income countries (LMICs).

KEYWORDS: *antimicrobial resistance; infection control; antimicrobial stewardship; One Health; MRSA; carbapenem resistance; global public health; bacteriophage therapy; WHO priority pathogens; GLASS surveillance.*

1. INTRODUCTION

The post-antibiotic era is no longer a distant theoretical concern but a present clinical reality. Antimicrobial resistance arises when microorganisms, bacteria, viruses, fungi, and parasites, evolve mechanisms to withstand the drugs designed to kill or inhibit them, rendering standard treatments ineffective and increasing the risk of disease spread, severe illness, and death.[1,2]

In 2022, Murray et al. published the landmark Global Research on Antimicrobial Resistance (GRAM) study, attributing 1.27 million deaths directly to AMR in 2019 and associating 4.95 million deaths with AMR-associated infections across 204 countries.[1] These figures significantly exceeded earlier projections and repositioned AMR as a leading cause of global mortality, surpassing HIV/AIDS and malaria in some regions. Sub-

Saharan Africa and South Asia bear disproportionate shares of this burden, reflecting inequities in access to clean water, sanitation, antibiotic quality control, and healthcare infrastructure.[1,2]

In healthcare settings, AMR directly undermines infection control measures. Multidrug-resistant organisms (MDROs) such as methicillin-resistant *Staphylococcus aureus* (MRSA), carbapenem-resistant Enterobacteriaceae (CRE), and extended-spectrum beta-lactamase (ESBL)-producing organisms have become endemic in many tertiary hospitals globally.[3–5] Their persistence in healthcare environments necessitates prolonged isolation precautions, increases healthcare-associated infection (HCAI) rates, prolongs hospitalisation, and escalates costs.[6,7]

The pharmaceutical sciences play a critical role in addressing AMR through the development of novel antibiotics, pharmacokinetic/pharmacodynamic (PK/PD) optimisation strategies, drug repurposing, and formulation science that ensures bioavailability in target tissues.[8,9] Yet the antibiotic development pipeline has remained alarmingly thin for decades, with major pharmaceutical companies withdrawing from the field due to economic disincentives.[10,11] This review consolidates current evidence on AMR's epidemiology, mechanisms, infection control implications, and novel therapeutic strategies, with the aim of informing clinical practice and pharmaceutical research agendas.

2. Mechanisms of Antimicrobial Resistance

2.1 Intrinsic and Acquired Resistance

Resistance mechanisms are broadly classified as intrinsic (naturally occurring structural features) or acquired (through mutation or horizontal gene transfer). Gram-negative bacteria exhibit intrinsic resistance to many antibiotics via outer membrane impermeability and constitutive efflux pump expression, while acquired resistance is frequently mediated by plasmid-borne resistance genes that can spread rapidly across species boundaries.[3,4]

2.2 Beta-Lactamase Production

The production of beta-lactamase enzymes remains the most clinically important resistance mechanism globally. ESBLs hydrolyse third-generation cephalosporins and monobactams, while carbapenemases, including KPC, NDM, OXA-48, and VIM variants, confer resistance to carbapenems, the antibiotics of last resort for many Gram-negative infections.[4,5] The emergence of OXA-48-producing *Klebsiella pneumoniae* across European hospitals and NDM-1-positive organisms across South Asia and Africa represents a critical epidemiological challenge.[5,12] Figure 1 shows the scientifically accurate infographic showing the four main AMR mechanisms in a Gram-negative bacterial cell.



Figure 1: Schematic of the four major AMR mechanisms in a Gram-negative bacterial cell: beta-lactamase-mediated inactivation, efflux pump overexpression, target-site modification, and reduced outer membrane permeability.

Caption: *A scientifically accurate infographic showing the four main AMR mechanisms in a Gram-negative bacterial cell: (1) beta-lactamase enzyme inactivating a beta-lactam antibiotic shown entering the periplasm, (2) efflux pumps actively expelling antibiotic molecules across the inner membrane, (3) modified penicillin-binding protein (PBP2a) preventing antibiotic binding at the target site, (4) reduced outer membrane porins limiting drug entry.*

Source: Adapted from current literature. References.[3–5]

2.3 Efflux Pumps and Porin Mutations

Efflux pump overexpression, particularly the resistance-nodulation-division (RND) family in Gram-negatives, actively exports a broad spectrum of antibiotics before they reach target concentrations. Combined with porin channel mutations that reduce cellular permeability,

these mechanisms create a 'double barrier' particularly evident in *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, both WHO critical priority pathogens.[3,13]

2.4 Horizontal Gene Transfer and Mobile Genetic Elements

Horizontal gene transfer (HGT) via conjugation, transformation, and transduction enables resistance genes to spread across diverse bacterial populations with alarming speed. Integrons, transposons, and resistance plasmids serve as vehicles for multi-drug resistance gene clusters. The prevalence of class 1 integrons carrying genes encoding resistance to aminoglycosides, sulphonamides, and trimethoprim has been documented in both clinical and environmental settings, highlighting AMR as a One Health challenge.[14–16]

3. Epidemiology and Global Burden

The global epidemiology of AMR is characterised by significant geographic heterogeneity, driven by differences in antibiotic consumption patterns, agricultural practices, water and sanitation infrastructure, and healthcare system capacity.[1,2] The WHO GLASS 2022 report documented increasing rates of carbapenem-resistant organisms across all participating WHO regions, with the highest prevalence observed in the Eastern Mediterranean and South-East Asian regions.[2] Table 1. Global Economic and Mortality Burden of AMR by Region.

Table 1. Global Economic and Mortality Burden of AMR by Region.

Region	AMR Deaths/yr (est.)	Economic Burden (USD)	Data Source	Reference
Sub-Saharan Africa	230,000+	$3.4 billion annual GDP loss	IHME 2022	[1]
South & Southeast Asia	300,000+	Projected $1.2 trillion by 2050	World Bank / OECD 2022	[2]
Europe	~35,000	€1.5 billion/year healthcare costs	ECDC 2022	[12]
North America	~35,000 (US alone)	$4.6 billion/year (US)	CDC 2022	[17]
Latin America	~90,000	Significant; data incomplete	PAHO / GLASS 2022	[2]
Global Total	~1.27 million attributable	$100 billion/year projected by 2050	Murray et al. 2022	[1]

Sources: Estimates derived from [1], [2], [12], and.[17] GDP = gross domestic product.

In Europe, the European Centre for Disease Prevention and Control (ECDC) estimated that AMR is responsible for approximately 35,000 deaths annually, with an economic burden exceeding €1.5 billion in direct healthcare costs.[12] In the United States, the CDC's 2022 AMR Threats Report identified 18 resistance threats causing over 2.8 million infections and 35,000 deaths per year.[17] Sub-Saharan Africa remains the most severely affected region in absolute mortality terms, with limited surveillance capacity compounding accurate quantification of the true burden.[1,2] Figure 2 presents a professional choropleth world map showing antimicrobial resistance burden (deaths per 100,000 population) by geographic region.



Figure 2: Choropleth world map showing AMR deaths per 100,000 population by WHO region (2019), with Sub-Saharan Africa and South Asia displaying the highest burden.

Caption: *A professional choropleth world map showing antimicrobial resistance burden (deaths per 100,000 population) by geographic region.*

Sources: Author's illustration compiled from references.[1,2]

4. WHO Priority Pathogens and Clinical Significance

In 2017, and reaffirmed in subsequent AMR action plans, the WHO published its Priority Pathogens List (PPL), categorising bacteria into critical, high, and medium priority tiers based on antibiotic resistance, mortality, community burden, preventability, treatability, healthcare burden, and pipeline requirements.[3] This framework remains the cornerstone for directing pharmaceutical investment and public health resources.

Table 2. WHO Priority Pathogens: Resistance Phenotypes and Clinical Impact

Priority Tier	Pathogen	Resistance Phenotype	Clinical Impact	Reference
Critical	Acinetobacter baumannii	Carbapenem-resistant	High mortality in ICU; limited treatment options	[3,4]
Critical	Pseudomonas aeruginosa	Carbapenem-resistant	Nosocomial infections; biofilm formation	[3]
Critical	Enterobacteriaceae	ESBL/Carbapenem-resistant (CRE)	Bloodstream infections; gut colonisation	[4,5]
High	Enterococcus faecium	Vancomycin-resistant (VRE)	Hospital-acquired; immunocompromised risk	[13]
High	Staphylococcus aureus	MRSA	Skin, bone, bloodstream infections	[13,14]
High	Helicobacter pylori	Clarithromycin-resistant	Peptic ulcer disease; eradication failure	[18]
Medium	Streptococcus pneumoniae	Penicillin non-susceptible	Meningitis, pneumonia burden	[19]
Medium	Haemophilus influenzae	Ampicillin-resistant	Paediatric respiratory disease	[19]

Sources: Adapted from references [1] and [3]. *ESBL = extended-spectrum beta-lactamase; CRE = carbapenem-resistant Enterobacteriaceae; MRSA = methicillin-resistant S. aureus; VRE = vancomycin-resistant Enterococcus; ICU = intensive care unit.*

Carbapenem-resistant *A. baumannii* (CRAB) has emerged as a particularly lethal pathogen in intensive care units, with crude mortality rates for CRAB bloodstream infections ranging from 40–70% in published series.[3,4] CRE infections caused by KPC-producing *K. pneumoniae* are associated with 30-day mortality of 30–50%, and their control requires concerted infection prevention strategies including active surveillance, contact precautions, and environmental decontamination.[5,20]

5. Infection Prevention and Control: AMR Implications

5.1 Healthcare-Associated Infections and MDRO Transmission

Healthcare-associated infections (HCAIs) caused by MDROs represent a direct and measurable consequence of AMR in clinical settings. MDROs can persist on environmental surfaces, medical equipment, and healthcare workers' hands for extended periods, facilitating nosocomial transmission.[6,7] The critical link between AMR and IPC is bidirectional: inadequate IPC practices accelerate AMR selection and spread, while high AMR prevalence renders IPC-relevant infections, such as central line-associated bloodstream infections (CLABSI) and ventilator-associated pneumonia (VAP), increasingly difficult to treat.[6,21] Table 3 shows the Evidence-Based Infection Control Strategies for AMR Containment.

Table 3. Evidence-Based Infection Control Strategies for AMR Containment.

Strategy	Core Components	Evidence Base	Reference
Hand Hygiene	WHO 5 Moments; alcohol-based handrub; compliance audits	Reduced HCAI rates by 15–40% in multimodal programmes	[6,7]
Contact Precautions	PPE use; patient cohorting; single-room isolation	Significantly reduced MRSA/VRE transmission	[6]
Antimicrobial Stewardship (AMS)	Prospective audit; de-escalation; IV-to-oral switch; DOT metrics	Reduced resistance emergence and CDI rates	[22,23]
Environmental Cleaning	Enhanced terminal cleaning; UV decontamination; ATP monitoring	Reduction in environmental pathogen burden	[7]
Active Surveillance Cultures	Admission screening; PCR-based detection for CRE/MRSA	Early detection enables targeted isolation	[20]
Vascular Access Bundles	CLABSI prevention: aseptic insertion, daily line review, prompt removal	Reduces CR-BSI and associated AMR selection pressure	[21]

PPE = personal protective equipment; HCAI = healthcare-associated infection; CDI = Clostridioides difficile infection; CLABSI = central line-associated bloodstream infection; DOT = days of therapy.
Sources: Compiled from references [6],[7],[21]and[22].

5.2 Antimicrobial Stewardship Programmes

Antimicrobial stewardship programmes (ASPs) are systematically implemented interventions to optimise antibiotic prescribing, reduce inappropriate use, and mitigate resistance selection pressure.[22,23] Core ASP strategies include prospective audit and feedback, pre-authorisation requirements for broad-spectrum agents, IV-to-oral switch protocols, de-escalation based on culture and sensitivity results, and days-of-therapy (DOT) metrics for performance monitoring.[22]

A 2021 systematic review and meta-analysis demonstrated that implementation of ASPs in hospital settings was associated with a 19.1% reduction in antibiotic use and significant reductions in Clostridioides difficile infection rates, MRSA acquisition, and ESBL organism prevalence.[23] In low- and middle-income country contexts, adapted ASP frameworks utilising locally trained pharmacists and infectious disease clinicians have shown comparable efficacy when supported by appropriate infrastructure.[16,23] Figure 3 shows a professional flowchart diagram illustrating the hospital antimicrobial stewardship programme (ASP) cycle.



Figure 3: Circular framework diagram of a hospital ASP showing five pillars- Prescriber Education, Pre-authorisation/Formulary Restriction, Prospective Audit & Feedback, IV-to-Oral Switch, and Outcome Monitoring (DOT metrics).

Caption: *A professional flowchart diagram illustrating the hospital antimicrobial stewardship programme (ASP) cycle. Show five interconnected pillars arranged in a circular framework: (1) Prescriber Education (books/graduation icon), (2) Pre-authorisation / Formulary Restriction (gate icon), (3) Prospective Audit & Feedback (magnifying glass icon), (4) IV-to-Oral Switch (syringe-to-pill icon), (5) Outcome Monitoring - DOT metrics and resistance trends (graph icon).*
Sources: Adapted from references.[22,23]

6. One Health Approach and Environmental Dimensions

The One Health framework recognises that human health, animal health, and ecosystem health are inextricably linked, and that AMR must be addressed across all three domains simultaneously.[15] Agricultural antibiotic use, comprising an estimated 70% of global antibiotic consumption, exerts powerful selection pressure on environmental and zoonotic bacterial populations.[15] The spread of ESBL-producing bacteria through contaminated water supplies, food chains, and soil represents a direct transmission pathway from animal and environmental reservoirs to human clinical settings.[16]

A 2023 multinational surveillance study documented the presence of carbapenem resistance genes (including *bla*NDM and *bla*OXA-48) in municipal wastewater, hospital effluent, and agricultural runoff samples across 12 countries, underscoring the environmental mobilisation of resistance determinants. [16] National AMR action plans aligned with the WHO Global Action Plan on AMR (2015, updated 2023) are required to incorporate environmental monitoring, veterinary stewardship, and water/sanitation interventions as core pillars of a comprehensive One Health response.[15,16]

7. Novel Therapeutic Strategies and the Drug Development Pipeline

7.1 Status of the Antibiotic Pipeline

The antibiotic development pipeline remains critically underfunded and insufficiently innovative to address the spectrum of emerging AMR threats.[10,11] As of 2024, the

WHO's antibacterial pipeline report identified fewer than 50 antibiotics in clinical development globally, with the majority representing modifications of existing classes rather than structurally novel agents. This creates 'class-level vulnerabilities' where resistance to one agent confers cross-resistance to related drugs.[10] Table 4 shows the Novel and Pipeline Antibiotics and Alternative Therapies (2020–2025).

Table 4. Novel and Pipeline Antibiotics and Alternative Therapies (2020–2025).

Agent / Therapy	Class / Mechanism	Target Pathogen	Development Stage	Reference
Cefiderocol	Siderophore cephalosporin	CR-GNB, A. baumannii	FDA approved 2019; global trials ongoing	[10]
Imipenem-relebactam	Carbapenem + β-lactamase inhibitor	CRE, P. aeruginosa	Phase III / Approved USA	[10,11]
Phage therapy	Bacteriophage lysis	Personalised MDR infections	Compassionate use; clinical trials	[24]
CRISPR-Cas9 antimicrobials	Gene editing; targeted killing	Sequence-specific pathogens	Preclinical / Phase I	[25]
Zoliflodacin	Spiropyrimidinetrione; DNA gyrase inhibitor	N. gonorrhoeae (MDR)	Phase III completed	[11]
Gepotidacin	Triazaacenaphthylene; type IIA topoisomerase inhibitor	UTIs; N. gonorrhoeae	Phase III / Submitted FDA	[11]

CR-GNB = carbapenem-resistant Gram-negative bacteria; MDR = multidrug-resistant; UTI = urinary tract infection; FDA = US Food and Drug Administration.

Sources: Compiled from references.[10],[11],[24],[25]

7.2 Bacteriophage Therapy

Bacteriophage therapy has re-emerged as a potentially transformative approach to MDR infections, particularly where conventional antibiotics have failed.[24] Phages are viruses that selectively infect and lyse bacteria without harming human cells, and their specificity can be exploited through personalised phage cocktails tailored to an individual patient's infecting organism. Compassionate use cases published between 2020–2024 include successful treatment of recalcitrant *A. baumannii* prosthetic valve endocarditis and refractory MRSA bacteraemia.[24] Phase I/II clinical trials are ongoing in the United States, United Kingdom, and Australia.[24]

7.3 CRISPR-Based Antimicrobials and Immunotherapies

Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas systems offer a precision approach to AMR through sequence-specific targeting of resistance genes within bacterial populations.[25] CRISPR-based antimicrobials can be designed to selectively kill bacteria harbouring specific resistance determinants, for instance, carbapenemase-encoding plasmids, without disrupting commensal microbiota.[25] While still at preclinical and early Phase I stages, this technology represents a paradigm shift in anti-infective drug design with profound implications for pharmaceutical science. Figure 4 presents the horizontal pipeline diagram showing the antibiotic and alternative therapy development stages.



Figure 4: Horizontal pipeline diagram from Discovery/Preclinical through Phase I–III to Approved/Market, populated with representative agents including CRISPR-Cas9 (Preclinical), phage therapy candidates (Phase I), novel beta-lactamase inhibitor combinations (Phase II), Zoliflodacin and Gepotidacin (Phase III), and Cefiderocol and Imipenem-relebactam.

Caption: *A horizontal pipeline diagram showing the antibiotic and alternative therapy development stages from left (Discovery/Preclinical) through Phase I, Phase II, Phase III, to Approved/Market. Preclinical-CRISPR-Cas9 antimicrobials; Phase I- novel phage therapy candidates; Phase II- new beta-lactamase inhibitor*

combinations; Phase III-Zoliflodacin, Gepotidacin; Approved- Cefiderocol, Imipenem-relebactam
Sources: Adapted from references.[10,11,24,25]

8. Policy, Governance, and Global Action

Global AMR governance requires multi-sectoral coordination at national and international levels. The WHO Global Action Plan on AMR provides a five-objective framework covering awareness, surveillance, infection prevention, antibiotic use optimisation, and investment in new medicines. [2,15] By 2025, 177 WHO Member States had developed National Action Plans (NAPs) on AMR, though implementation fidelity remains highly variable, particularly in LMICs with constrained health financing.[2]

Push and pull incentive mechanisms are increasingly recognised as necessary to revitalise pharmaceutical investment in antibiotic research and development.[8,10] 'Push' mechanisms include public research funding, tax credits, and grants; 'pull' mechanisms such as the transferable exclusivity voucher model (proposed in the US PASTEUR Act) and subscription-based reimbursement models (piloted in the UK and Sweden) decouple antibiotic revenue from sales volume, addressing the fundamental market failure in antibiotic economics.[8,10,11] International coordination bodies, including CARB-X, GARDP, and the AMR Action Fund, have committed over $1.1 billion to early-stage antibiotic development since 2020.[10,11]

9. CONCLUSION

Antimicrobial resistance stands as a defining public health challenge of the 21st century, with consequences spanning clinical medicine, pharmaceutical science, global health equity, and environmental sustainability. The convergence of MDR pathogen proliferation, a depleted antibiotic pipeline, and inadequate global governance creates compounding vulnerabilities in health systems worldwide. Addressing AMR demands an integrated response: strengthening infection prevention and control programmes in healthcare facilities, scaling antimicrobial stewardship, accelerating the development and equitable distribution of novel therapeutics, implementing One Health surveillance across human, animal, and environmental sectors, and establishing sustainable economic models for antibiotic innovation. Pharmaceutical scientists, clinicians, policymakers, and public health professionals must collaborate urgently to reverse the trajectory of AMR before the post-antibiotic era becomes an irreversible reality.

Conflict of Interest: The authors declare no conflicts of interest.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES

1. Murray CJ, Ikuta KS, Sharara F, et al.; Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325): 629–655.
2. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2022. Geneva: WHO; 2022.
3. Tacconelli E, Carrara E, Savoldi A, et al.; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet. Infect. Dis., 2018; 18(3): 318–327.
4. Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin. Microbiol. Infect., 2018; 24(2): 133–144.
5. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017; 8(4): 460–469.
6. World Health Organization. Guidelines on Core Components of Infection Prevention and Control Programmes at the National and Acute Health Care Facility Level. Geneva: WHO; 2016 (updated implementation guide 2021).
7. Cassini A, Högberg LD, Plachouras D, et al.; Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet. Infect. Dis., 2019; 19(1): 56–66.
8. Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet. Infect. Dis., 2016; 16(4): 500–505.
9. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis., 1998; 26(1): 1–10.
10. World Health Organization. 2021 Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis. Geneva: WHO; 2022.
11. Theuretzbacher U, Outterson K, Engel A, Karlén A. The global preclinical antibacterial pipeline. Nat. Rev. Microbiol., 2020; 18(5): 275–285.
12. European Centre for Disease Prevention and Control (ECDC). Antimicrobial Resistance in the EU/EEA (EARS-Net): Annual Epidemiological Report for 2021. Stockholm: ECDC; 2022.
13. Nigo M, Hasbun R, Musher DM, et al. Staphylococcal bacteremia in the 21st century: a review of current challenges and therapeutic options. Open Forum Infect. Dis., 2021; 8(3): ofab085.
14. Strich JR, Palmore TN. Preventing transmission of multidrug-resistant pathogens in the intensive care unit. Infect. Dis. Clin. North Am., 2017; 31(3): 535–550.

15. Robinson TP, Bu DP, Carrique-Mas J, et al. Antibiotic resistance is the quintessential One Health issue. Trans. R. Soc. Trop. Med. Hyg., 2016; 110(7): 377–380.
16. Hendriksen RS, Munk P, Njage P, et al.; Global Sewage Surveillance Project Consortium. Global monitoring of antimicrobial resistance based on metagenomics analyses of urban sewage. Nat. Commun., 2019; 10(1): 1124.
17. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2022 Update. Atlanta, GA: CDC; 2022.
18. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018; 155(5): 1372–1382.
19. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022; 400(10369): 2221–2248.
20. Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant Enterobacteriaceae. Clin. Infect. Dis., 2014; 58(5): 697–703.
21. Septimus EJ. Antimicrobial resistance: an antimicrobial/diagnostic stewardship and infection prevention approach. Med. Clin. North Am., 2023; 107(2): 421–435.
22. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin. Infect. Dis., 2016; 62(10): e51–e77.
23. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet. Infect. Dis., 2017; 17(9): 990–1001.
24. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin. Microbiol. Rev., 2019; 32(2): e00066-18.
25. Bikard D, Euler CW, Luo W, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol., 2014; 32(11): 1146–1150.